TORONTO -A critic of the pharmaceutical industry says Health Canada's approach to drug regulation puts too much emphasis on speeding up drug approvals and too little on following the safety profile of drugs once they hit the market.
Dr. Joel Lexchin also says the Food and Drugs Act doesn't give Health Canada enough tools to deal with safety concerns that arise once drugs are approved for sale in this country.
Lexchin, who teaches at York University in Toronto, says Health Canada can't make a drug company recall medications from store shelves or compel a company to change the safety labelling on an approved drug.
No comments:
Post a Comment